Lin BioScience
6696Taipei, Taiwan· Est.
Taiwan‑based biotech developing oral small‑molecule drugs for eye disease, cancer and metabolic disorders, with multiple FDA‑designated clinical programs.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Taiwan‑based biotech developing oral small‑molecule drugs for eye disease, cancer and metabolic disorders, with multiple FDA‑designated clinical programs.
OphthalmologyOncologyMetabolic Disease
Technology Platform
Proprietary oral small‑molecule platform, including an RBP4 antagonist for retinal degeneration and natural product‑derived inhibitors for cancer, leveraging structure‑based design and high‑throughput screening.
Opportunities
Successful Phase 3 and Phase 1/2 data could attract strategic partnerships or licensing deals, leveraging the oral administration advantage across ophthalmology and oncology markets.
Risk Factors
Clinical trial outcomes remain uncertain, and the company faces competition from larger firms developing oral and injectable therapies for the same indications.
Competitive Landscape
Lin BioScience competes with both biotech and pharma companies developing oral treatments for retinal disease and leukemia, differentiating itself through its RBP4 antagonist and natural small‑molecule inhibitor platforms.